Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1025

BMO Capital analyst Evan Kurtz maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $1001 to $1025.
byBenzinga Newsdesk
March 14, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

BMO Capital analyst Evan Kurtz maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $1001 to $1025.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0